Company
Roche
Roche has 91 drugs tracked on RxWires: 8 post-market, 7 approved, 26 in Phase 3, 28 in Phase 2, 4 in Phase 1/2, 16 in Phase 1.
- Ticker
- RHHBY
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| oseltamivir [Tamiflu] | Post-Market | Influenza |
| Risdiplam | Post-Market | Muscular Atrophy, Spinal |
| Peginterferon alfa-2a | Post-Market | Hepatitis B, Chronic |
| peginterferon alfa-2a [Pegasys] | Post-Market | Hepatitis C, Chronic |
| calcipotriol hydrate [Daivonex] | Post-Market | Psoriasis |
| enfuvirtide | Post-Market | HIV Infections |
| rituximab [MabThera/Rituxan] | Post-Market | Rheumatoid Arthritis |
| Daclizumab | Post-Market | Heart Transplantation |
| TECENTRIQ | Approved | |
| MIRCERA | Approved | |
| GANTRISIN | Approved | |
| TARACTAN | Approved | |
| CELLCEPT | Approved | |
| ARFONAD | Approved | |
| EVEX | Approved | |
| Tocilizumab | Phase 3 | Rheumatoid Arthritis |
| Satralizumab | Phase 3 | Neuromyelitis Optica (NMO) |
| Enicepatide | Phase 3 | Obesity or Overweight |
| Crovalimab | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria |
| Tiragolumab | Phase 3 | Non-Small Cell Lung Cancer |
| Divarasib | Phase 3 | Non-small Cell Lung Cancer |
| Petrelintide | Phase 3 | Obesity or Overweight |
| Trontinemab | Phase 3 | Alzheimer's Disease |
| Pertuzumab | Phase 3 | Solid Tumors |
| Obinutuzumab | Phase 3 | Lymphoma |
| Afimkibart | Phase 3 | Moderately to Severely Active Crohns Disease |
| Ranibizumab | Phase 3 | Neovascular Age-related Macular Degeneration |
| Ipatasertib | Phase 3 | Cancer |
| bevacizumab [Avastin] | Phase 3 | Pancreatic Cancer |
| DMARD | Phase 3 | Rheumatoid Arthritis |
| Faricimab | Phase 3 | Macular Edema |
| NXT007 | Phase 3 | Hemophilia A |
| RO4917838 | Phase 3 | Schizophrenia |
| methotrexate | Phase 3 | Rheumatoid Arthritis |
| Rituximab | Phase 3 | Chronic Lymphocytic Leukemia |
| Prasinezumab | Phase 3 | Parkinson's Disease |
| Emicizumab | Phase 3 | Hemophilia A |
| Docetaxel plus Capecitabine | Phase 3 | Breast Neoplasms |
| Cevostamab | Phase 3 | Multiple Myeloma |
| Ocrelizumab | Phase 3 | Multiple Sclerosis |
| tocilizumab [RoActemra/Actemra] | Phase 3 | Rheumatoid Arthritis |
| methoxy polyethylene glycol-epoetin beta [Mircera] | Phase 2 | Anemia |
| Fenebrutinib | Phase 2 | Relapsing Multiple Sclerosis |
| RO7568282 | Phase 2 | Parkinson's Disease |
| RO7269162 | Phase 2 | Alzheimer's Disease |
| Inavolisib | Phase 2 | Metastatic Castration-Resistant Prostate Cancer |
| Selinexor | Phase 2 | Smoldering Multiple Myeloma |
| cytarabine | Phase 2 | Myelodysplastic Syndromes, Myelogenous Leukemia, Acute |
| Giredestrant | Phase 2 | Breast Cancer |
| aleglitazar | Phase 2 | Diabetes Mellitus Type 2 |
| 5-Fluorouracil | Phase 2 | Breast Cancer |
| Autogene Cevumeran | Phase 2 | Muscle-invasive Urothelial Carcinoma |
| taspoglutide | Phase 2 | Diabetes Mellitus Type 2 |
| Qutenza (8% capsaicin) | Phase 2 | Pulmonary Hypertension |
| bevacizumab (Avastin) | Phase 2 | Liver Cancer |
| PolyPEPI1018 | Phase 2 | Colorectal Cancer Metastatic |
| Paclitaxel | Phase 2 | Ovarian Sex-cord Stromal Tumor |
| Capecitabine | Phase 2 | Metastatic Breast Cancer |
| Vixarelimab | Phase 2 | Prurigo Nodularis |
| Doxycline | Phase 2 | Non-Small Cell Lung Cancer |
| Zenapax | Phase 2 | Newly Diagnosed With Type 1 Diabetes |
| Ibrutinib | Phase 2 | Lymphoma |
| RAR Gamma | Phase 2 | Emphysema |
| Mosunetuzumab | Phase 2 | Lupus |
| delandistrogene moxeparvovec | Phase 2 | Duchenne Muscular Dystrophy |
| Lebrikizumab | Phase 2 | Asthma |
| KPL-716 | Phase 2 | Chronic Idiopathic Urticaria |
| Copegus | Phase 2 | Hepatitis C, Chronic |
| Alectinib | Phase 2 | Non-small Cell Lung Cancer |
| Regorafenib | Phase 1/2 | Colorectal Cancer |
| Dulanermin | Phase 1/2 | Non-Hodgkin's Lymphoma |
| Englumafusp alfa | Phase 1/2 | Lymphoma, Non-Hodgkin |
| SPK-8011QQ | Phase 1/2 | Hemophilia A |
| ribavirin [Copegus] | Phase 1 | Healthy Volunteer |
| RO7296682 | Phase 1 | Solid Tumors |
| RO7663498 | Phase 1 | Diabetic Retinopathy |
| RO7795081 | Phase 1 | Renal Impairment |
| Ocrelizumab Co-formulated With rHuPH20 | Phase 1 | Multiple Sclerosis |
| Nelfinavir mesylate | Phase 1 | HIV Infections |
| RO6889450 | Phase 1 | Healthy Volunteer |
| ketoconazole | Phase 1 | Malignant Melanoma, Neoplasms |
| RO5083945 | Phase 1 | Neoplasms |
| RG1507 | Phase 1 | Neoplasms |
| RO7062931 | Phase 1 | Healthy Participants |
| tocilizumab [RoActemra/Actemra] Syringe | Phase 1 | Healthy Volunteer |
| RO6870810 | Phase 1 | Solid Tumors, Advanced Solid Tumors |
| RO4995819 | Phase 1 | Healthy Volunteer |
| GDC-7035 | Phase 1 | Colorectal Neoplasms |
| GDC-9545 | Phase 1 | Breast Cancer |
| Zalcitabine | Not Applicable | HIV Infections |
| 3.75% Imiquimod Cream | Not Applicable | Mycosis Fungoides |
Latest
Follow Roche on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.